A Phase 2b/3 study to evaluate the safety tolerability and effects of Livoletide (AZP-531) an unacylated ghrelin analog on food-related behaviors in patients with Prader-Willi syndrome
Brief description of study
The purpose of this research is to test if a drug called livoletide will have an effect on hyperphagia (feeling of insatiable hunger) and food-related behaviors for patients with Prader-Willi syndrome. The study will also test if livoletide is safe and well tolerated.
Clinical Study Identifier: s19-00201
ClinicalTrials.gov Identifier: NCTs19-00201
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
